drug_type
RELEVANT_DRUG
intervention_type
Targeted therapy
drug_description
Monoclonal antibody targeting HER2 that blocks ligand-dependent HER2 dimerization, complementing trastuzumab.
nci_thesaurus_concept_id
C38692
nci_thesaurus_preferred_term
Pertuzumab
nci_thesaurus_definition
A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)
drug_mesh_term
Pertuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized monoclonal antibody against HER2 that binds the extracellular dimerization domain (subdomain II), blocking ligand-dependent HER2 heterodimerization—especially HER2:HER3—thereby inhibiting downstream PI3K/AKT and MAPK signaling, reducing proliferation and promoting tumor cell death; complements trastuzumab.
drug_name
Pertuzumab
nct_id_drug_ref
NCT06490536